Abstract
Introduction
Pentisomide, 2-[2-diisopropylamino)-ethyl]-4-methyl-2-(2-pyridyl)-pentanamide, a derivative of disopyramide (1) , is a new Class I antiarrhythmic drug currently under investiga tion for ventricular (2) (3) (4) and supraventricular (5-8) arrhyth mias. Experimental studies indicate that its main action is the inhibition of the fast sodium channel (9-11), whereas its calcium blocking effects are probably not of clinical relevance (12) .
Although the efficacy of antiarrhythmic drugs often does not correlate directly with serum level, the determination of serum levels is recommended where drug therapy is ineffective in order to differentiate failure of therapy from suboptimal dosing. This procedure is especially important for elderly pa tients with decreased creatinine clearance (13) .
The aim of the present study was to develop a simple but ac curate high-performance liquid chromatographic (HPLC) method to determine pentisomide and its mono-N-dealkylated metabolite in human serum. (Grom, Herrenberg, Germany) at room temperature (20°C). The mobile phase consisted of 74% v/v eluent A (962 mL water, 25 mL PIC B8 low UV reagent, 1 mL triethylamine, 12 mL PIC D4 reagent) and 26% v/v eluent Β (acetonitrile). The flow rate was 1.0 mL/min. The column effluent was monitored at 260 nm using a detector range of 0.02 AUFS and a chart speed of 0.5 cm/min. The injected volume was 200 µL.
Standards
Three stock standard solutions were prepared; each con tained 20 µg/mL pentisomide, its metabolite, or an internal standard in 0.01M hydrochloric acid. The solutions were stable for at least 4 months if stored at 4°C. A standard working solu tion was obtained by combining aliquots of the stock solutions and diluting them with hydrochloric acid to concentrations of 2.0 µg/mL for pentisomide and its metabolite and 3.0 µg/mL for the internal standard.
Sample collections
Serum was obtained by centrifugation at 900 × g for 10 min. Twenty-two serum samples from normal volunteers (12 male, 10 female) were pooled (normal pool). Serum levels of penti somide and its metabolite were determined in 12 patients on the fifth day of oral treatment with pentisomide for control of supraventricular tachycardia. Patients received 900 mg penti somide per day if their bodyweight was 80 kg or less; they re ceived 1200 mg per day if their bodyweight was above 80 kg. Serum samples from the 12 patients were taken before and 3 h after oral intake; the results were 900 mg and 1200 mg penti somide, respectively.
Extraction procedure
Dichloromethane (2 mL), serum (1.0 mL), 0.1M sodium hy droxide (100 µL), and the stock solution of the internal standard (100 µL) were introduced into a 10-mL glass centrifuge tube (Kästner; Tubingen, Germany). The tube was closed with a stopper (Sarstedt; Nürnbrecht, Germany), shaken for 1 min, and centrifuged at 3600 × g for 10 min. The serum phase was subsequently discarded, and 1.0 mL of the dichloromethane phase was transferred to a clean glass tube and evaporated to dryness at room temperature (20°C) under a stream of ni trogen. The residue was redissolved in 500 µL of 0.01M hy drochloric acid.
Linearity test
The linearity of the chromatographic procedure was tested for pentisomide, its metabolite, and the internal standard by an alyzing eight standard solutions with concentrations of 10.0, 5.0, 2.5,1.25, 0.63, 0.31, 0.16 and 0.08 µg/mL for each of the components. The solutions were obtained by diluting the stan dard solutions containing pentisomide, its metabolite, and the internal standard. At each concentration step, three determi nations were performed. Each standard (100 µL) was intro duced into a glass centrifuge tube, and 1.0 mL of the normal pool serum was added. The spiked serum samples were ex tracted and subjected to chromatographic analysis. Three de terminations were performed at each concentration.
Recovery rates
The recovery rates were determined by comparing the peak areas of pentisomide, its metabolite, and the internal standard, which were obtained by analyzing a spiked serum sample (100 µL of each stock solution standard plus 1.0 mL of the normal pool), with the peak areas obtained by direct injection of the standard working solution (2.0 µg/mL pentisomide, 2.0 µg/mL metabolite, and 3.0 µg/mL of the internal standard). This pro cedure was repeated with different drug concentrations (see Table I ).
Quantitation
Prior to injection of each patient probe, the standard working solution of pentisomide, its metabolite (2.0 µg/mL each), and the internal standard (3.0 µg/mL) were injected. Because there was a linear relationship between the peak area and the con centration of pentisomide and its metabolite, concentrations of pentisomide or its metabolite in the patient probe were calcu lated using the following equation: 
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where A P is the peak area of pentisomide or the metabolite in the patient probe; A S is the peak area of pentisomide or the metabolite in the standard working solution; C P is the concen tration of pentisomide or the metabolite in the patient probe; C s is the concentration of pentisomide or the metabolite in the standard solution; and R IS is the recovery rate of the internal standard. Both concentrations are given in micrograms per milliliter. Because the recovery of pentisomide and the metabolite in the patient probe might change in various extractions, it was calculated by dividing the peak area of the internal standard of the patient probe with the peak area of the internal standard in the standard working solution (Equation 2). The recovery rates of all three substances were within 5%. The concentration of pentisomide and the metabolite in the patient probe was de termined (micrograms per milliliter) by taking into account the concentrations of the two substances in the standard working solution (C S in Equation 1).
Eq2
A PI is the peak area of the internal standard in the patient probe, and A SI is the peak area of the internal standard in the standard working solution.
Results
For the standards, as well as for the entire procedure, there was a linear relationship between concentration and peak area over the total range tested. The lower limit of quantitation of all three substances was 0.028 g/mL. The recovery rates of 10 de terminations (mean plus or minus standard deviation) obtained with four different drug concentrations (see Table I ) were 92.6 ± 2.7% for pentisomide, 92.2 ± 2.8% for the metabolite, and 95.3 ± 2.9% for the internal standard. These recovery rates were consistent across the high and low concentrations (see Table I ). Serum levels of one serum sample determined re peatedly over the course of 1 year were stable (storage at -20°C). We did not observe any interference in the chromato graphic procedure by other drugs as listed in Table II . The precision of the assay was assessed by replicate analyses of spiked plasma samples containing pentisomide and its metabolite at concentrations of 1, 2, and 5 µg/mL. The intraassay and inter-assay coefficients of variation are presented in Table III . The within-day and between-day variation at each concentration for both drugs was less than 7%.
The serum levels of pentisomide and the metabolite before and 3 h after oral intake on the fifth day of treatment with pentisomide are presented in Table IV . Serum levels of penti somide were not different for patients treated successfully with pentisomide and patients in whom the tachycardia was still inducible in an electrophysiologic study. Pa tients with low drug concentrations did not take a different concomitant medication than patients with higher drug levels. A typical chromatogram obtained from the analysis of a serum sample of a patient re ceiving pentisomide (900 mg/day) is shown in Figure 2 . Three HPLC methods that use ultraviolet detection (14-16) and one gas chromato graphic (GC) method that uses thermionic detection (17) have been described for mea surement of pentisomide in human serum.
Discussion
The main disadvantage of the GC methods is that additional steps, such as separate as says or derivatization procedures, are re quired to determine metabolite concentra tions. HPLC techniques allow simultaneous assay of the drug and its major metabolite in the same sample with use of a common in ternal standard. Reliable determinations of the metabolite are important because drug metabolites may add or alter the effects of the parent compound by exerting similar ac tions, competing with the parent compound, or mediating drug toxicity (18) .
Necciari and co-workers (17) reported re covery rates of pentisomide ranging from 59.3% to 67.5%. Houin and co-workers (14) also demonstrated a relatively moderate re covery of 60% and 69% for the metabolite and pentisomide, respectively, probably due to the complicated liquid-liquid extraction procedure, which was used by both authors (14, 17) . This procedure requires a back extraction into an acidic buffer and contains altogether three phase separations consuming nearly 60 min. Walker and co-workers (15) achieved satisfactory recovery for pentisomide (95% ±1.9%) but needed a high sensitivity assay in addition to a direct-extraction pro cedure in order to improve the recovery rate of the metabolite from 74% ± 1.6% to 79% ± 2.5%. In addition, only three de terminations for each substance were performed to evaluate the respective recovery rates. Furthermore, the high sensitivity assay was necessary to detect drug levels below 0.5 mg/L. Be cause it is difficult to predict drug levels after antiarrhythmic therapy (19) , two extraction procedures might be necessary to obtain samples ready for HPLC injection, which would result in a waste of specimens. The HPLC method described by Plomp and Buijs (16) involves extraction of samples via activated Bond Elut C 8 disposable columns that require repeated washing pro cedures with methanol, water, and acetonitrile. In addition, the collected eluates have to be evaporated to dryness under a nitrogen stream and reconstituted in the mobile phase used in that assay. This is a potent extraction procedure with recoveries of 91.1% for pentisomide, 93.8% for the metabolite, and 90% for the internal standard, but such equipment is not available in all clinical laboratories. Because these extraction columns may be reused at least five times, this method is far more ex pansive than our extraction procedure, which is supposed to be used for a large number of samples in clinical practice.
The mean recovery rates in our extraction procedure were 92.2% ± 2.8% for the metabolite and 92.6% ± 2.7% for penti somide. All necessary steps for extraction required approxi mately 15 min. With the dichloromethane-serum ratio used, we did not see any emulsification. Ultraviolet detection was performed at 260 nm, which was the determined absorbance peak for pentisomide and its metabolite. Wavelengths of 254 nm (14) and 258 nm (17) were used in other reports.
The metabolite, pentisomide, and the internal standard were eluted with retention times of 6.3, 8.5, and 16.9 min, respectively, whereas the reten tion times of pentisomide and its metabolite reported by the other methods occurred within 3 min; thus there were possible peak interferences. The specificity of the method is excellent, as demonstrated by the lack of interference from endogenous material. No interference was noted after the addition of 29 drugs that may be administered with pen tisomide. Even disopyramide and the betablocking agents acebutolol and metoprolol did not interfere with pentisomide, contrary to other reports (15) (16) (17) . Serum samples can be stored at -20°C for at least a year without deterioration of the drug. This method is accurate, rapid, and inex pensive. It is suitable for monitoring thera peutic and toxic serum levels of pentisomide and its metabolite.
We determined pentisomide and metabo lite serum levels in patients treated with pentisomide for supraventricular tachycardia. The determined serum levels showed a high interindividuel variability. This variability was in dependent of concomitant drug medication or impaired renal function; efficient control of supraventricular tachycardia and side effects were not dependent on pentisomide or its metabo lite serum level in this small patient group. Plasma levels of pentisomide and its metabolite are in good agreement with previous reported plasma levels (16) . Most patients treated with 1200 mg pentisomide had drug levels above those of patients treated with the minor dosage (900 mg), though bodyweight was the factor used to determine treatment dosage.
Conclusion
This newly developed, sensitive, and selective HPLC method is suitable for simple, rapid, and accurate monitoring of serum levels of pentisomide and its metabolite in clinical practice. Serum levels were determined in patients after oral treatment with pentisomide for control of supraventricular tachycardia.
